CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Clinical Trials
475
Active:296
Completed:140
Trial Phases
5 Phases
Phase 1:246
Phase 2:50
Phase 3:55
+2 more phases
Drug Approvals
86
CIMA_AEMPS:26
EMA:23
CANADA:12
+2 more agencies
Drug Approvals
Beclometasone Dipropionate and Formoterol Fumarate Powder for Inhalation
- Product Name
- 倍氯米松福莫特罗吸入粉雾剂
- Approval Number
- 国药准字HJ20240144
- Approval Date
- Dec 1, 2024
NMPA
Beclometasone Dipropionate Suspension for Inhalation
- Product Name
- 吸入用丙酸倍氯米松混悬液
- Approval Number
- 国药准字HJ20130214
- Approval Date
- Feb 14, 2023
NMPA
Beclometasone Dipropionate，Formoterol Fumarate and Glycopyrrolate Inhalation Aerosol
- Product Name
- 倍氯福格吸入气雾剂
- Approval Number
- 国药准字HJ20220035
- Approval Date
- Apr 12, 2022
NMPA
Budesonide Pressurised Inhalation Solution
- Product Name
- 布地奈德吸入气雾剂
- Approval Number
- H20120320
- Approval Date
- Feb 13, 2020
NMPA
Clinical Trials
Distribution across different clinical trial phases (363 trials with phase data)• Click on a phase to view related trials
Phase 1
246 (67.8%)Phase 3
55 (15.2%)Phase 2
50 (13.8%)Phase 4
10 (2.8%)Not Applicable
2 (0.6%)Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects
Not Applicable
Not yet recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Biological: CHF6467 Part 1 (SAD)Drug: PlaceboBiological: CHF6467 Part 2 (MAD)
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 68
- Registration Number
- NCT07163182
- Locations
- 🇧🇬
Bulgaria MC Comac Medical Ltd., Sofia, Bulgaria
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Not yet recruiting
- Conditions
- Fabry DiseasePregnancyPregnancy Complications
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06941025
- Locations
- 🇬🇧
No physical study sites - Decentralized, web-based registry, London, United Kingdom
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Phase 3
Recruiting
- Conditions
- Epidermolysis BullosaJunctional Epidermolysis BullosaEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, JunctionalSkin AbnormalitiesCongenital AbnormalitiesConnective Tissue DiseaseCollagen DiseasesSkin DiseasesGenetic Diseases, Inborn
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT06917690
- Locations
- 🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵Niigata University Medical and Dental Hospital, Niigata, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Japan
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06900816
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 30
- Registration Number
- NCT06892756
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria
- Prev
- 1
- 2
- 3
- 4
- 5
- 35
- Next
News
Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants
Elgan Pharma and Chiesi Group have dosed the first patients in FIT-PIV, a Phase 3 trial evaluating ELGN-2112 for intestinal malabsorption in preterm infants.